Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the <scp>MCRN</scp> ?003/ <scp>MYX</scp> .1 single arm phase <scp>II</scp> trial

The MCRN-003/CCTGMYX.1 is a single arm phase II trial of weekly carfilzomib, cyclophosphamide and dexamethasone (wKCd), exploring convenient immunomodulator (IMiD)-free regimen in relapsed myeloma. Weekly carfilzomib (20/70 mg/m2), 40 mg 300 mg/m2 was delivered over 28-day cycles. primary endpoint overall response after four Secondary endpoints included toxicity, depth, PFS OS. Exploratory the impact cytogenetics, prior therapy exposure serum free light chain (sFLC) escape; 76 patients were accrued. ORR 85% (68% ?very good partial [VGPR] 29% ?complete [CR]). median OS 27 17 months respectively. High-risk cytogenetics conferred worse (75% vs. 97%, p = .013) (18 NR, .002) with trend toward (14 22 months, .06). Prior proteasome inhibitor (PI) or lenalidomide did not influence PFS. sFLC noted 15% when as progression event. most common ? grade 3 non-hematologic adverse events infectious (40%), vascular (17%) cardiac (15%). wKCD safe effective relapse, especially for ineligible lenalidomide-based therapies.